- Category: Experimental HCV Drugs
- Published on Monday, 24 March 2014 00:00
- Written by Gregory Fowler
As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.
In conjunction with the Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston, hepatitis C experts Michael Saag of the University of Alabama at Birmingham, Daniel Fierer of the Ichan School of Medicine at Mt. Sinai, Anita Kohli of the National Institutes of Health, and Arthur Kim of Harvard Medical School joined HIVandHepatitis.com editor Liz Highleyman to discuss these and other topics on a panel sponsored by IFARA.
[Michael Saag, Liz Highleyman, Daniel Fierer, Anita Kohli, and Arhur Kim, IFARA hepatitis C panel, March 5, 2014]
IFARA Hepatitis C panel. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, March 5, 2014.MORE TEXT
[IFARA hepatitis C panel atCROI 2014, March 5, 2014]
IFARA. Advances in Hepatitis C Treatment: the Future Is Now. March 5, 2014.